According to a new study done by a team of University of Liverpool, on the world’s 20 top-selling drugs, it was known that on an average the U.S is selling its popular drugs at a price which is three times what is sold in Britain.
Without the government control over drug prices, the stickers for meds have gone higher and higher.
These meds are accounted for 15% of the global pharma spending in 2014 which have brought in huge amount of money for the companies such as AbbVie ($ABBV), AstraZeneca ($AZN), Merck ($MRK), Pfizer ($PFE) and Roche ($RHHBY). 
The difference isn't just in the U.K., though. Researchers found that U.S. prices were consistently higher than in other European markets, too. And elsewhere around the world, U.S. prices came in at 6 times those in Brazil and 16 times higher than average in the lowest-price country--usually India.
It's just another reason pricing critics are calling for reform and government intervention in the U.S., which lacks spending-control strategies like government negotiations and drug price caps, and leaves pricing to market competition instead. A 5000% price increase by Turing Pharmaceuticals recently prompted presidential candidate Hillary Clinton to unroll plans to fight rising prices, spooking investors and putting a chill on the pharma sector.
Drugmakers, of course, have their justifications for keeping U.S. prices high. And as pharma trade group PhRMA pointed out, those lofty list prices don't take into account the discounts that insurers snag through "aggressive negotiation."
PhRMA also contends that while U.S. patients pay more for drugs when they first hit the market, prices decline after drugs go off patent; 90% of all meds prescribed to Americans are now cheap generics, and in Britain, generics make up just over 75% of prescriptions.
But that argument doesn't apply to biologics--yet. Right now, there's only one lower cost copy of a biologic on the U.S. market, and that's a Novartis ($NVS) version of Amgen's ($AMGN) Neupogen. Therapies such as AbbVie's Humira--the best-selling drug in the world--don't have cheaper competition, though that should change in the coming years; industry-watchers expect Humira knockoffs to eventually rank among the most successful biosimilars out there, a Bloomberg Intelligence survey found in June.
"The U.S. has a competitive marketplace that works to control costs while encouraging the development of new treatments and cures," Holly Campbell, PhRMA's director of communications, said in a statement.
The U.K., though, sees discounts, too. It employs a body of cost-effectiveness gatekeepers that drugmakers must get past to gain access to the market, and that process often requires offering up price cuts through so-called "patient-access schemes."
View Latest News: